Free Trial
Fall Lock-In Sale! MarketBeat All Access, $149 a Year for Life
Lock In $149
Claim MarketBeat All Access Sale Promotion
NASDAQ:LTRN

Lantern Pharma Q3 2026 Earnings Date & Estimates

Lantern Pharma logo
$0.62 -0.01 (-1.83%)
Closing price 04:00 PM Eastern
Extended Trading
$0.65 +0.03 (+4.04%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Lantern Pharma is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026. The conference call is scheduled for November 12, 2026 at 9:00 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Conference Call Date
Conference Call
9:00 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Lantern Pharma in Q3 2026

Lantern Pharma is expected to post earnings of -$0.35 per share. In the same quarter a year earlier Lantern Pharma reported -$0.39 per share. Lantern Pharma last reported on August 14, 2026, posting -$0.57 per share and missing the -$0.38 consensus estimate. Lantern Pharma has beaten the consensus EPS estimate in 6 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.35
Prior-Year EPS
-$0.39

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.57 (Missed by -$0.19)
EPS Beat Rate
6 of last 8 quarters

Prepare for the Q3 2026 Call

Lantern Pharma Q3 2026 Earnings FAQ

Lantern Pharma (NASDAQ:LTRN) is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026. This date is estimated from past reporting schedules and may change once the company confirms it.

Lantern Pharma's Q3 2026 earnings conference call is scheduled for Thursday, November 12, 2026 at 9:00 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Lantern Pharma to post earnings of -$0.35 per share for Q3 2026.

Lantern Pharma Earnings Headlines

Lantern Pharma Highlights AI Pipeline, LP-300 Data and Open-Medicine Spinout Plans
October 17, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31128709
New to The Street Show 775 Premieres Tonight on Bloomberg Television Across the United States, Latin America, MENA and Southeast Asia, Featuring American Fusion, HPB, T-REX ...
October 10, 2026  |  usatoday.comhttps://www.usatoday.com/press-release/story/48601/new-to-the-street-show-775-premieres-tonight-on-bloomberg-television-across-the-united-states-latin-america-mena-and-southeast-asia-featuring-american-fusion-hpb-t-rex-acquisition-corp-and-syncm/
Nvidia's $550 Trillion Problem
Do not buy another AI stock until you've seen the arithmetic below. Nvidia is worth about $5.5 trillion. Alphabet about $4.1 trillion. Microsoft about $3.8 trillion. So what would it take to repeat Nvidia's run? A 100x gain from here puts Nvidia near $550 trillion. Nothing in history has ever been worth that. Big money in Nvidia has already been made. By the people who bought it years ago. But that does not mean the AI boom is finished. It means the opportunity has moved underneath it... to the layer every AI company has to pay to use.tc pixel
October 26 at 1:00 AM  |  Decentralized Masters (Ad)
Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 15th, 2026
October 8, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/lantern-pharma-present-thinkequity-conference-120000133.html
LTRN Share News Today
October 7, 2026  |  uk.investing.comhttps://uk.investing.com/equities/lantern-pharma-inc-news
Lantern Pharma Receives Taiwan Approvals to Open Next Stage of Phase 2 HARMONIC™ Trial of LP-300 in Never-Smoker, EGFR-Mutant NSCLC
October 7, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20261007674654/en/Lantern-Pharma-Receives-Taiwan-Approvals-to-Open-Next-Stage-of-Phase-2-HARMONIC%E2%84%A2-Trial-of-LP-300-in-Never-Smoker-EGFR-Mutant-NSCLC/
See More Lantern Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Lantern Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lantern Pharma and other key companies, straight to your email.

About Lantern Pharma

Lantern Pharma (NASDAQ:LTRN), Inc. is a clinical-stage biopharmaceutical company focused on developing precision cancer therapies. The company combines artificial intelligence, machine learning and genomic analysis to identify drug candidates, patient populations and biomarkers that may support more targeted oncology treatments.

Lantern Pharma’s technology platform, RADR, is designed to analyze large volumes of biological, genomic and clinical data to help accelerate drug discovery and development. The platform is used to evaluate existing and novel therapeutic compounds, identify potential mechanisms of action and support the development of biomarker-driven clinical programs.

The company’s oncology pipeline has included investigational therapies for solid tumors and hematologic cancers, including programs such as LP-184 and LP-284. Lantern Pharma advances these candidates through preclinical research and clinical development, with a focus on cancers where genomic characteristics may help identify patients most likely to respond to treatment.

Lantern Pharma was founded in 2013 and is headquartered in Dallas, Texas. Panna Sharma serves as the company’s chief executive officer and president. Its shares trade on the Nasdaq Capital Market under the symbol LTRN.

View Lantern Pharma Profile
Earnings Tools